Shanghai – October 21, 2024 – Cooley advised Akeso (Hong Kong Stock Exchange code: 9926.HK), a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing and commercializing innovative medicines that address global medical needs, on its HK$1.9 billion (approximately US$250 million) follow-on public offering. Akeso offered an aggregate of 31,700,000 shares, priced at HK$61.28 per share. Morgan Stanley acted as the sole overall coordinator and sole placing agent of the offering. Akeso will use 70% of the financing for global and China clinical development of core products and other clinical pipeline products in oncology and immunology; 20% for the commercialization of existing approved products; and 10% for general corporate use.
Partners Yiming Liu and Michael Yu led the Cooley team advising Akeso.
Cooley previously advised Akeso on its approximately HK$1.2 billion (US$149.53 million) follow-on public offering in March 2024 and its collaboration agreement with Pfizer in August 2021.
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,300+ lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.